New stock news: Zhejiang Jingxin Pharmaceutical (002020.SZ) plans to launch a Hong Kong IPO. The China Securities Regulatory Commission requires additional clarification on the compliance of overseas investment and other regulatory procedures of its overseas subsidiaries.

The China Securities Regulatory Commission issued the "Requirements for Supplemental Materials for Overseas Issuance and Listing Filings (May 25, 2026 - May 29, 2026)." The International Division of the China Securities Regulatory Commission has issued supplemental material requirements for 11 companies. Among them, Zhejiang Jingxin Pharmaceutical (002020.SZ) is required to provide additional explanations on the specific compliance of overseas subsidiaries' involvement in overseas investments, foreign exchange management, and other regulatory procedures. According to the disclosure by the Hong Kong Stock Exchange on February 11, Zhejiang Jingxin Pharmaceutical Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities as its exclusive sponsor. The China Securities Regulatory Commission has requested Zhejiang Jingxin Pharmaceutical to supplement the following information, and legal counsel is to verify and provide clear legal opinions: Please provide additional information on the specific compliance of overseas subsidiaries' involvement in overseas investments, foreign exchange management, and other regulatory procedures, and provide a conclusion on compliance. The prospectus shows that Zhejiang Jingxin Pharmaceutical is a pharmaceutical group focused on innovation, with strategic emphasis on two core disease areas: central nervous system diseases; and cardiovascular and cerebrovascular diseases. The company adheres to a business model that combines the commercialization of existing products with the continuous advancement of product pipelines. In recent years, the company has focused its strategic emphasis on the research and development of innovative drugs in the areas of central nervous system diseases and cardiovascular and cerebrovascular diseases. The current product portfolio includes drugs (including generics, innovative drugs, traditional Chinese medicine, and biologics); raw materials; and medical devices.